Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Amneal Pharma ((AMRX)) has held its Q4 earnings call. Read on for the main highlights of the call. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.

It is worth considering Amneal Pharmaceuticals (AMRX), which belongs to the Zacks Medical - Drugs industry. When looking at the last two reports, this pharmaceutical company has recorded a strong ...